CDC-RFA-CK-26-0107: Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases
Closed
This grant is closed. A newer notice from the same program is forecast: Early Detection, Response, and Control of Global Rabies Outbreaks and Associated Threats to America's Dog-Rabies Free Status (RFA-CK-27-106). Status: Expected deadline February 1, 2027. It is in our archive of Centers for Disease Control - NCEZID notices from 2026.
Centers for Disease Control - NCEZID offered grants of up to $30.0 million (at least $200,000) to any type of organization. It expected to make about 30 awards worth $150 million in total. Applications closed on July 1, 2026.
From the official notice on Grants.gov, last changed June 2, 2026. Checked November 7, 2026.
- Award ceiling$30.0 million
- Award floor$200,000
- Total funding$150 million
- Expected awards30
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | June 1, 2026 |
|---|---|
| Deadline | July 1, 2026 |
| Archived by Grants.gov | July 31, 2026 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Faith Based Organizations
Is this a realistic fit?
- Past Prevention of Disease, Disability, and Death by Infectious Diseases awards averaged $1.9 million; this notice allows up to $30.0 million per award.
- No cost sharing or match is required.
What the grant funds
This cooperative agreement establishes a single, integrated funding mechanism aimed at enhancing the nation's ability to prevent, detect, and respond to infectious disease threats. It will support clinicians, healthcare professionals, healthcare systems, institutions, and organizations directly involved in patient care, public health, and infectious disease control across the United States. By strengthening the capacity of these key stakeholders, the program will enable more effective frontline engagement, facilitate the implementation of timely public health responses, and generate expert insights to inform and improve public health guidance and practice. The program will focus on building and sustaining critical infrastructure, workforce training, communication strategies, and emergency response capabilities needed to address both emerging and reemerging infectious diseases. Emphasis will be placed on expanding national infection prevention capacity through targeted education and training initiatives, particularly in the areas of antimicrobial resistance and infection control. Additionally, the program will enhance preparedness by supporting surge staffing and fostering coordination among healthcare and public health partners during emergency response efforts.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before
From fiscal 2021 to 2025, Prevention of Disease, Disability, and Death by Infectious Diseases (93.084) awarded $241 million across 128 grant awards, an average of $1.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Puerto Rico Science, Technology, and Research Trust | Puerto Rico | 4 | $14.5 million |
| Massachusetts Department of Public Health | Massachusetts | 1 | $11.6 million |
| Emory University | Georgia | 3 | $11.5 million |
| Uganda Virus Research Institute | 1 | $8.7 million | |
| Ponce Medical School Foundation Inc | Puerto Rico | 2 | $8.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, RFA-CK-27-106, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CK-26-0107 still open?
No. It closed on July 1, 2026. A newer notice is forecast: RFA-CK-27-106, expected deadline February 1, 2027.
Who can apply for Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases?
Centers for Disease Control - NCEZID accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases?
Closed July 1, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $30.0 million each. About $150 million in total across about 30 awards.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before?
The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)